Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,814,005	$ 11,437,118
Supplies for clinical trials	0	1,186,186
Other assets	2,589,032	791,485
Total current assets	4,403,037	13,414,789
Property and equipment, net	76,633	109,823
Supplies for clinical trials	0	1,309,648
Deposits	0	1,955,514
Deferred offering costs	330,871	100,216
Total assets	4,810,541	16,889,990
Current liabilities:
Accounts payable	4,250,826	1,342,126
Accrued compensation and benefits	201,643	1,109,864
Accrued liabilities	3,267,704	786,953
Total current liabilities	7,720,173	3,238,943
CIRM liability	0	6,945,741
Warrant liability	27,862	573,560
Total liabilities	7,748,035	10,758,244
Commitments and contingencies (Note 5)
Shareholders’ equity (deficit):
Preferred stock $0.0001 par value, 1,000,000 shares authorized; 0 shares outstanding as of June 30, 2017 and December 31, 2016	0	0
Common stock, $0.0001 par value; 25,000,000 shares authorized; 3,551,575 and 3,444,859 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	355	344
Additional paid-in capital	102,719,728	102,354,844
Accumulated deficit	(105,657,577)	(96,223,442)
Total shareholders’ equity (deficit)	(2,937,494)	6,131,746
Total liabilities and shareholders’ equity (deficit)	$ 4,810,541	$ 16,889,990